Skip to main content
. 2016 Nov 7;16:858. doi: 10.1186/s12885-016-2901-1

Table 5.

Items regarding CS4: Patient with non-functioning GEP-NET, non-susceptible to surgery or to loco-regional treatment, with Ki-67 < 10 %, ECOG ≤2, AND NEGATIVE OCTREOSCAN®: Is SSA treatment initiated? [11, 48, 49, 68]

graphic file with name 12885_2016_2901_Tab5_HTML.jpg

CS Clinical situation, SSAs Somatostatin analogs, GEP Gastroenteropancreatic, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement, D Disagreement, I Indeterminate

aOnly applies to statements with 2 rounds; participant % in median range: median range

Shadowed boxes: non-consensus